Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Caris Life Sciences (CAI) EBIT Margin (2024 - 2025)

Caris Life Sciences has reported EBIT Margin over the past 2 years, most recently at 30.19% for Q4 2025.

  • Quarterly results put EBIT Margin at 30.19% for Q4 2025, up 5870.0% from a year ago — trailing twelve months through Dec 2025 was 8.04% (changed N/A YoY), and the annual figure for FY2025 was 5.56%, up 6792.0%.
  • EBIT Margin for Q4 2025 was 30.19% at Caris Life Sciences, up from 15.05% in the prior quarter.
  • Over the last five years, EBIT Margin for CAI hit a ceiling of 30.19% in Q4 2025 and a floor of 66.98% in Q2 2024.